Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib
Anaplastic lymphoma kinase (ALK) rearrangements represent the molecular driver of a subset of non-small cell lung cancers (NSCLCs). Despite the initial response, virtually all ALK-positive patients develop an acquired resistance to the ALK inhibitor crizotinib, usually within 12 months. Several next-generation ALK inhibitors have been developed in order to overcome crizotinib limitation, providing an unprecedented survival for this subset of patients. The aim of this review to summarize the current knowledge on ALK tyrosine kinase inhibitors (TKIs) in the treatment of advanced ALK-positive NSCLC, focusing on the role of novel ALK inhibitors in this setting. In addition, we will discuss their role in the pharmacological management of ALK-positive brain metastasis. Next-generation ALK inhibitors showed an impressive clinical activity in ALK-positive NSCLC, also against the sanctuary site of CNS. Sequential therapy with ALK TKIs appears to be effective in patients who fail a first ALK TKI and translates in clinically meaningful benefit. However, these agents display different activity profiles against crizotinib resistance mutation; therefore re-genotyping the disease at progression in order to administer the right TKI to the right patient is going to be necessary to correctly tailor the treatment. To avoid repeated invasive procedure, noninvasive methods to detect and monitor ALK rearrangement are under clinical investigation.
KeywordsNSCLC ALK rearrangement Tyrosine kinase inhibitors Brain metastasis
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Research involving human participants and/or animals
This article does not contain any studies with human participants or animals performed by any of the authors.
Informed consent was not required for this study.
- 2.Howlader N, Noone AM, Krapcho M, et al., editors. SEER cancer statistics review, 1975–2012. Bethesda: National Cancer Institute; 2015.Google Scholar
- 10.Li T, Maus MK, Desai SJ, et al. Large-scale screening and molecular characterization of EML4-ALK fusion variants in archival non-small-cell lung cancer tumor specimens using quantitative reverse transcription polymerase chain reaction assays. J Thorac Oncol. 2014;9(1):18–25.CrossRefPubMedGoogle Scholar
- 20.Kim DW, Ahn MJ, Shi Y, et al. Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC). J Clin Oncol. 2012;30(15):Suppl7433.Google Scholar
- 21.Blackhall F, Ross Camidge D, Shaw AT, et al. Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer. ESMO Open. 2017;2(3):e000219.CrossRefPubMedPubMedCentralGoogle Scholar
- 23.Shaw AT, Pasi AJ, Besse B, et al. Crizotinib vs chemotherapy in ALK+ advanced non-small cell lung cancer (NSCLC): final survival results from PROFILE 1007. J Clin Oncol. 2016;34(15):Suppl.9066.Google Scholar
- 31.Rossing HH, Grauslund M, Urbanska EM, et al. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report. BMC Res Notes. 2013;6:489.CrossRefPubMedPubMedCentralGoogle Scholar
- 40.Marsilje TH, Pei W, Chen B, et al. Synthesis, structure-activity relationship, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and 2 clinical trials. J Med Chem. 2013;56(14):5675–90.CrossRefPubMedGoogle Scholar
- 43.Crinò L, Ahn MJ, De Marinis F, et al. Multicenter phase II study of whole-body and intracranial activity with ceritinib in patients with ALK-rearranged non-small-cell lung cancer previously treated with chemotherapy and crizotinib: results from ASCEND-2. J Clin Oncol. 2016;34(24):2866–73.CrossRefPubMedGoogle Scholar
- 44.Felip E, Orlov S, Park K, et al. ASCEND-3: A single-arm, open-label, multicenter phase II study of ceritinib in ALKi-naïve adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC). J Clin Oncol. 2015;33:abstr 8060.Google Scholar
- 47.Cho BC, Kim DW, Bearz A, et al. ASCEND-8: a randomized phase 1 study of ceritinib, 450 mg or 600 mg, taken with a low-fat meal versus 750 mg in fasted state in patients with anaplastic lymphoma kinase (ALK)-rearranged metastatic non-small cell lung cancer (NSCLC). J Thorac Oncol. 2017;12(9):1357–67.CrossRefPubMedGoogle Scholar
- 52.Gadgeel SM, Gandhi L, Riely GJ, et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol. 2014;15(10):1119–28.CrossRefPubMedGoogle Scholar
- 57.Bauer TM, Shaw AT, Solomon B, et al. Phase I/II study of PF-06463922, an ALK/ROS1 tyrosine kinase inhibitor, in patients with advanced non-small-cell lung cancer harboring specific molecular alterations. J Clin Oncol. 2015;33:abstrTPS2620.Google Scholar
- 58.Johnson TW, Richardson PF, Bailey S, et al. Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations. J Med Chem. 2014;57(11):4720–44.CrossRefPubMedGoogle Scholar
- 63.Solomon B, Shaw A, Ou S, et al. Phase 2 study of lorlatinib in patients with advanced ALK+/ROS1+ non-small-cell lung cancer. J Thorac Oncol. 2017;11S2:OA0506.Google Scholar
- 67.Langer CJ, Gettinger SN, Bazhenova L, et al. Activity and safety of brigatinib (BRG) in patients (pts) with ALK+ non–small cell lung cancer (NSCLC): phase (ph) 1/2 trial results. J Clin Oncol. 2016;34(Suppl.15):abstr9057.Google Scholar
- 76.Ou SHI, Azada M, Hsiang DJ, et al. Next-generation sequencing reveals a novel NSCLCALK f1174v mutation and confirms ALKG1202R mutation confers high-level resistance to alectinib (ch5424802/ro5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib. J Thorac Oncol. 2014;9(4):549–53.CrossRefGoogle Scholar
- 80.Maitland ML, Ou SHI, Tolcher AW, et al. Safety, activity, and pharmacokinetics of an oral anaplastic lymphoma kinase (ALK) inhibitor, ASP3026, observed in a “fast follower” phase 1 trial design. J Clin Oncol. 2014;32(5s):abstr2624.Google Scholar
- 81.Arkenau H, Sachdev J, Mita M, et al. Phase (Ph) 1/2a study of TSR-011, a potent inhibitor of ALK and TRK, in advanced solid tumors including crizotinib-resistant ALK positive non-small cell lung cancer. J Clin Oncol. 2015;33:abstr8063.Google Scholar
- 83.Horn L, Infante JR, Blumenschein GR, et al. A phase I trial of X-396, a novel ALK inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2014;32(5s):abstr8030.Google Scholar
- 86.Gadgeel S, Shaw T, Govindan R, et al. Pooled analysis of CNS response to alectinib in two studies of pre-treated ALK+ NSCLC. J Thorac Oncol. 2015;10(9Suppl 2):S238(abstract).Google Scholar
- 88.Tiseo M, Huber RM, Hochmair MJ, et al. Brigatinib in ALK-positive NSCLC pts with intracranial CNS metastases in 2 clinical trials. Ann Oncol. 2017;28(Suppl.2):ii28–51.Google Scholar
- 89.Riely GJ, Yu HA, Stephens D, et al. A phase 1 study of crizotinib and ganetespib (STA-9090) in ALK positive lung cancers. J Clin Oncol. 2015;33:abstr 8064.Google Scholar
- 91.Spigel DR, Reynolds C, Waterhouse D, et al. Phase 1/2 study of the safety and tolerability of nivolumab plus crizotinib for the first-line treatment of ALK translocation–positive advanced non-small cell lung cancer (CheckMate 370). J Thorac Oncol. 2018; pii:S1556-0864(18)30176-X.Google Scholar
- 92.Felip E, De Braud FG, Maur M, et al. Ceritinib plus nivolumab (NIVO) in patients (pts) with anaplastic lymphoma kinase positive (ALK+) advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2017;35(15suppl):2502.Google Scholar